A N Ananthakrishnan1, A Sakuraba2, E L Barnes3, J Pekow2, L Raffals4, M D Long3, R S Sandler5. 1. Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 2. Inflammatory Bowel Disease Center and Division of Gastroenterology, University of Chicago, Chicago, IL, USA. 3. Division of Gastroenterology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 4. Division of Gastroenterology, Mayo Clinic, Rochester, MN, USA. 5. Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Abstract
BACKGROUND: The impact of combination therapy on disease-related morbidity in patients with established Crohn's disease (CD) or ulcerative colitis (UC) remains to be well-defined. AIM: To examine the effect of combination therapy on disease outcomes in CD and UC. METHODS: Using a multicenter prospective cohort, we classified CD and UC patients as being on monotherapy with anti-TNF or on combination with an immunomodulator. The primary outcome was a composite of new IBD-related surgery, hospitalisations, penetrating complications, need for corticosteroids or new biological at 1 year. Multivariable regression models adjusted for potential confounders. RESULTS: We included 707 patients with CD (45% combination therapy) and 164 with UC (38% combination therapy). Combination therapy was not associated with reduction in the composite outcome in either CD (OR: 0.87, 95% CI: 0.63-1.22) or UC (OR: 1.45, 95% CI: 0.63-3.38). However, while no difference was noted in those with nonstricturing, nonpenetrating CD, a significant reduction in the likelihood of the outcome was seen in those with stricturing or penetrating CD (30% vs 39%, OR: 0.58, 95% CI: 0.37-0.90). A stronger effect was also observed in those with disease duration <5 years (OR: 0.35, 95% CI: 0.14-0.87) compared to those with a longer duration (OR: 0.75, 95% CI: 0.45-1.27). A similar reduction in occurrence of composite outcome was noted with infliximab and with other anti-TNF biologics. CONCLUSION: The benefit of combination immunomodulator-biological therapy is stronger in those with complicated Crohn's disease, particularly early on in their disease course.
BACKGROUND: The impact of combination therapy on disease-related morbidity in patients with established Crohn's disease (CD) or ulcerative colitis (UC) remains to be well-defined. AIM: To examine the effect of combination therapy on disease outcomes in CD and UC. METHODS: Using a multicenter prospective cohort, we classified CD and UC patients as being on monotherapy with anti-TNF or on combination with an immunomodulator. The primary outcome was a composite of new IBD-related surgery, hospitalisations, penetrating complications, need for corticosteroids or new biological at 1 year. Multivariable regression models adjusted for potential confounders. RESULTS: We included 707 patients with CD (45% combination therapy) and 164 with UC (38% combination therapy). Combination therapy was not associated with reduction in the composite outcome in either CD (OR: 0.87, 95% CI: 0.63-1.22) or UC (OR: 1.45, 95% CI: 0.63-3.38). However, while no difference was noted in those with nonstricturing, nonpenetrating CD, a significant reduction in the likelihood of the outcome was seen in those with stricturing or penetrating CD (30% vs 39%, OR: 0.58, 95% CI: 0.37-0.90). A stronger effect was also observed in those with disease duration <5 years (OR: 0.35, 95% CI: 0.14-0.87) compared to those with a longer duration (OR: 0.75, 95% CI: 0.45-1.27). A similar reduction in occurrence of composite outcome was noted with infliximab and with other anti-TNF biologics. CONCLUSION: The benefit of combination immunomodulator-biological therapy is stronger in those with complicated Crohn's disease, particularly early on in their disease course.
Authors: Giuseppe Murdaca; Francesca Spanò; Miriam Contatore; Andrea Guastalla; Elena Penza; Ottavia Magnani; Francesco Puppo Journal: Expert Opin Drug Saf Date: 2015-11-11 Impact factor: 4.250
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts Journal: Gastroenterology Date: 2014-02 Impact factor: 22.682
Authors: Abhinav Vasudevan; Ajay Raghunath; Shane Anthony; Cian Scanlon; Miles P Sparrow; Peter R Gibson; Daniel R van Langenberg Journal: Dig Dis Sci Date: 2018-12-17 Impact factor: 3.199
Authors: Edward L Barnes; Laura Raffals; Millie D Long; Gaurav Syal; Maia Kayal; Ashwin Ananthakrishnan; Benjamin Cohen; Joel Pekow; Parakkal Deepak; Jean-Frederic Colombel; Hans H Herfarth; Robert S Sandler Journal: Crohns Colitis 360 Date: 2020-07-24
Authors: Fernando Magro; Catarina Alves; Mafalda Santiago; Paula Ministro; Paula Lago; Luís Correia; Raquel Gonçalves; Diana Carvalho; Francisco Portela; Cláudia Camila Dias; Axel Dignass; Silvio Danese; Laurent Peyrin-Biroulet; Maria Manuela Estevinho; Paula Moreira Journal: United European Gastroenterol J Date: 2021-12-14 Impact factor: 4.623
Authors: Matthew Bohm; Ronghui Xu; Yiran Zhang; Sashidhar Varma; Monika Fischer; Gursimran Kochhar; Brigid Boland; Siddharth Singh; Robert Hirten; Ryan Ungaro; Eugenia Shmidt; Karen Lasch; Vipul Jairaith; David Hudesman; Shannon Chang; Dana Lukin; Arun Swaminath; Bruce E Sands; Jean-Frederic Colombel; Sunanda Kane; Edward V Loftus; Bo Shen; Corey A Siegel; William J Sandborn; Parambir S Dulai Journal: Aliment Pharmacol Ther Date: 2020-07-13 Impact factor: 9.524